Catálogo de publicaciones - libros
36th Hemophilia Symposium: Hamburg 2005
Inge Scharrer ; Wolfgang Schramm (eds.)
Resumen/Descripción – provisto por la editorial
Palabras clave – provistas por la editorial
Medicine & Public Health;
|Institución detectada||Año de publicación||Navegá||Descargá||Solicitá|
Tabla de contenidos
The Occurrence of Factor VIII Inhibitor in a Patient with Mild Hemophilia A - During Treatment with Interferon for Chronic Hepatitis C
W. Miesbach; B. Llugaliu; G. Asmelash; Ch. von Auer; I. Scharrer
Palabras clave: Factor Viii; Tooth Extraction; Recombinant Factor VIII; Factor Viii Activity; Bleeding Symptom.
Severe Hemophilia A Patient with High-Titer Inhibitor, use of TGA in the Monitoring of Bypassing Therapy
A. Hluši; P. Novák; V. Krčová; L. Slavik
In our first experience with TGA we observed its high sensitivity to inhibitor development. Generation of thrombin comes slower in despite of using by-pass agent. Minimum rate of thrombin sufficient for hemostasis is unknown and probably is individual. Duration of the measurement should be prolonged over 90 minutes. The assay has a potential for bypass therapy monitoring.
Palabras clave: Factor Viii; Thrombin Generation; Minimum Rate; Substitution Therapy; Severe Hemophilia.
EUREKA - an European Registry for Orthopedic Surgery in Hemophiliacs with Inhibitors
Palabras clave: Public Health; Surgical Procedure; Factor VIIa; Orthopedic Surgery; Line Treatment.
Double Balloon Enteroscopy (DBE) with Argon Plasma Laser Coagulation (APC) for a Patient with Heyde’s Syndrome
A. Trummer; F. Wiedbrauck; S. Hollerbach
Palabras clave: Aortic Stenosis; Aortic Valve Replacement; Capsule Endoscopy; Aortic Valve Stenosis; Effective Orifice Area.
Successful Liver Transplantation in a Patient with Anti-Thrombocyte Antibodies and Severe Hemophilia A
W. Miesbach; C. Zapletal; G. Asmelash; B. Llugalio; W. O. Bechstein; I. Scharrer
Palabras clave: Liver Transplantation; Liver Cirrhosis; Coagulation Disorder; Severe Hemophilia; Thrombocyte Count.
Peri- and Postoperative Course of 95 Patients with von-Willebrand’s Disease
Ch. von Auer; K. Lotter; S. Heinsdorf; I. Scharrer
The finding of 16 bleeding complications in 173 surgical interventions is low (9.2%). Most bleeding complications were seen in patients with vWD type 2B and 3. Patients who underwent major surgery and who received only Minirin had more often bleeding complications. Our evaluation of bleeding incidents in the context of surgery in vWD patients reveals the necessity of special hemostaseologic care for these patients. Substitution therapy should depend on vWD-type and type of surgical intervention.We recommend a therapy with vWF containing FVIII-products for major surgery in vWDpatients. Especially during thoracic surgery, gynecological and otolaryngological surgery a careful peri- and postoperative hemostaseologic management as well as careful coagulation techniques of the surgeon are required.
Palabras clave: Major Surgery; Bleeding Complication; Thyroid Gland Surgery; Substitution Therapy; Bleeding Pattern.
Pregnancy in a Patient with Congenital Antithrombin Deficiency
B. Maak; L. Kochhan; Ch. Estel; P. Heuchel
Palabras clave: Thrombotic Occlusion; Endogenous Thrombin Potential; Antithrombin Activity; Antithrombin Deficiency; Deficient Woman.
Successful Inhibitor-Elimination with Rituximab in Acquired Hemophilia A and a Patient with a Carrier Status for Hemophilia A: Two Case Reports
P. Lages; A. Huth-Kühne; R. Zimmermann
We successfully eliminated inhibitors in both patients and achieved a complete remission with Rituximab and Prednisone alone (Pat. B) and in combination with Cyclophosphamide (Pat. A). Although Rituximab has been reported to have relatively little toxicity, patient A (70 yrs.) was severely immunocompromized due to an additional dramatic drop of the CD4 cell count, resulting in a life-threatening pulmonary infection and long hospitalization. Our results indicate, that Rituximab therapy has a valuable effect in patients with AH and should be considered in severely affected patients where standard therapy has failed. An optimal initial approach for inhibitor eradication in AH remains to be defined. The additional use of Prednisone and/or Cyclophosphamide might provide a better outcome for a defined patient group. Therefore treatment regimens will have to be patient tailored. The optimum dose, treatment schedule and long-term side effects remain to be elucidated and warrant further investigation.
Palabras clave: Valuable Effect; Inhibitor Titer; Factor Viii Inhibitor; FVIII Activity; Bethesda Unit.
An Interesting Family Case of von-Willebrand-Syndrome
S. Gottstein; R. Schneppenheim; U. Budde; R. Klamroth
Palabras clave: Compartment Syndrome; Mutation Heterozygous; None None; History Taking; Coagulation Test.
Clinical Manifestations of Dysfibrinogenemia in Relation to the Fibrinogen Gene Mutation
W. Miesbach; V. Catania; M. Boehm; Th. Vigh; Ch. von Auer; I. Scharrer
Palabras clave: Fibrinogen Level; Bleeding Tendency; Fibrinogen Concentration; Radial Immunodiffusion; Measure Plasma Concentration.